(Press-News.org) A joint research team led by Dr. Gyujin Song of the Korea Institute of Energy Research (President: Yi, Chang-Keun, hereafter “KIER”), Dr. Kwon-Hyung Lee of the University of Cambridge, and Professor Tae-Hee Kim of the University of Ulsan has successfully developed a new dry-process manufacturing technology for secondary battery electrodes that overcomes the limitations of conventional electrode fabrication processes.
The technology developed by the research team is a dry manufacturing process that forms a dual-fibrous structure inside the electrode, simultaneously creating thin “thread-like” and thick “rope-like” fibers. This dual-fiber (dual-fibrous) architecture enables the technology to address both the low mixing strength and performance degradation issues of conventional dry processes at the same time.
Electrode manufacturing methods for secondary batteries are broadly divided into wet and dry processes, depending on whether a solvent is used. In the wet process, a binder* dissolved in a solvent is used as an adhesive, which ensures uniform mixing of the electrode materials. Owing to its high process reliability and advantages in securing performance, the wet process is currently the predominant method used for electrode fabrication.
* Binder: a polymer material used in manufacturing secondary-battery electrodes that holds together components such as the active material (which stores electrical energy) and the conductive additive (which carries electric current), so the electrode can stably maintain its form.
However, it relies on toxic organic solvents, which creates a heavy environmental burden, and the time required for drying and solvent recovery is long, leading to high production costs. As a result, there has recently been growing interest in developing dry-process technologies that do not use solvents.
The dry process does not use solvents, which allows for faster processing and helps reduce environmental pollution and energy consumption. However, because there is no solvent to dissolve the binder, only a limited range of binder materials can be used, such as polytetrafluoroethylene (PTFE)*, which stretches into fiber-like structures and physically holds the particles together.
* PTFE (Polytetrafluoroethylene): a material with excellent heat resistance and chemical resistance, widely known in everyday life as Teflon (a brand name of DuPont, USA) used for frying pan coatings.
As a result, in conventional dry processes it has been difficult to uniformly mix the electrode materials, and the low cohesion of the mixture has led to persistent concerns that the performance and durability of the finished batteries are degraded.
To overcome the structural limitations of the dry process, the researchers did not change the material of the conventional PTFE binder; instead, they controlled the physical structure of the same material to create a PTFE binder with a “dual-fiber” structure.
The research team designed an original multi-step process that divides the binder addition from a single step into two stages. First, they add a small amount of binder and carry out a primary mixing step, forming a fine, “thread-like” fibrous network that densely connects the active material and the conductive additive. Then, in a secondary mixing step, they add the remaining binder so that, while the existing fibrous network is maintained, an additional thick and robust “rope-like” fiber structure is formed.
The resulting fine, “thread-like” fibrous network uniformly disperses the constituent materials, such as the active material and conductive additive, thereby making the reactions more uniform and improving battery performance. In addition, the thick, “rope-like” fibers firmly bind the entire electrode together, significantly increasing its strength and mechanical stability and enhancing the durability required for mass-production processes.
In addition, analysis using electrochemical reaction-resistance mapping showed that all regions of the electrode exhibit fast and uniform reaction kinetics and resistance characteristics. This is a key factor in minimizing energy loss during battery operation, preventing performance degradation in specific areas, and thereby extending the overall lifetime of the cell.
In performance evaluations, the dry electrode developed by the research team achieved a high areal capacity of 10.1 mAh/cm². A pouch-type lithium metal anode cell using this electrode reached an energy density of 349 Wh/kg, about 40% higher than that of commercial electrodes, which are around 250 Wh/kg. In addition, a pouch cell using a graphite anode achieved an energy density of 291 Wh/kg, showing a value approximately 20% higher than that of a wet-process cell under the same conditions.
Dr. Gyujin Song, who led the research, stated, “This study is highly significant in that we have established an original process technology capable of simultaneously resolving the two core challenges of dry electrodes: electrochemical uniformity and mechanical durability. We expect it to not only enhance the cost competitiveness of the secondary battery industry, but also be applicable to electric vehicles and energy storage systems (ESS), which require high energy density.”
Meanwhile, this research was carried out with support from the Ministry of Science and ICT’s “Global TOP Research Program” and “Creative Allied Project,” and the results were published in the September issue of Energy & Environmental Science (IF 30.8), a world-renowned journal in the field of energy and the environment.
END
Weaving secondary battery electrodes with fibers and tying them like ropes for both durability and performance
KIER’s ‘Dual-Fiber’ dry electrode technology overcomes limits of conventional battery electrode manufacturing.
2025-12-08
ELSE PRESS RELEASES FROM THIS DATE:
Using social media may impair children’s attention
2025-12-08
Children who spend a significant amount of time on social media tend to experience a gradual decline in their ability to concentrate. This is according to a comprehensive study from Karolinska Institutet, published in Pediatrics Open Science, where researchers followed more than 8,000 children from around age 10 through age 14.
The use of screens and digital media has risen sharply in the past 15 years, coinciding with an increase in ADHD diagnoses in Sweden and elsewhere. Researchers at Karolinska Institutet in Sweden and Oregon Health ...
Science briefing: An update on GLP-1 drugs for obesity
2025-12-08
In a special 11 December event for science journalists, the Science Press Package team will revisit the topic recognized as Science’s Breakthrough of the year in 2023: the development of GLP-1 receptor agonists to treat obesity and their efficacy in blunting obesity-associated health problems. The Mani L. Bhaumik Breakthrough of the Year Award that the American Association for the Advancement of Science, publisher of Science, gave to researchers whose work best underpinned ...
Lower doses of immunotherapy for skin cancer give better results
2025-12-08
According to a new study, lower doses of approved immunotherapy for malignant melanoma can give better results against tumours, while reducing side effects. This is reported by researchers at Karolinska Institutet in the Journal of the National Cancer Institute.
“The results are highly interesting in oncology, as we show that a lower dose of an immunotherapy drug, in addition to causing significantly fewer side effects, actually gives better results against tumours and longer survival,” says last author Hildur Helgadottir, a researcher at the Department of Oncology-Pathology at Karolinska Institutet, who led the study.
The traditional ...
Why didn’t the senior citizen cross the road? Slower crossings may help people with reduced mobility
2025-12-08
Road crossings need to slow down to allow people with mobility issues and older pedestrians enough time to use them, research has indicated.
The time interval of crossings in the UK is more than two seconds shorter than people with reduced mobility need, according to a new study by researchers at the Universities of Bath, Birmingham and Exeter.
Led by Dr Max Western from the University of Bath Centre for Motivation and Behaviour Change, the study found that just 1.5% of older adults with ...
ASH 2025: Study suggests that a virtual program focusing on diet and exercise can help reduce side effects of lymphoma treatment
2025-12-07
MIAMI, FLORIDA (EMBARGOED UNTIL DEC. 7, 2025, AT 6:00 P.M. EST) – Patients undergoing treatment for lymphoma often experience adverse side effects that can be so severe that they stop or slow treatment. But a new study shows that a virtual program focusing on diet and exercise is a feasible strategy for minimizing the side effects of cancer therapies and increasing treatment retention.
Early findings from the LIFE-L study will be presented on behalf of the multidisciplinary team by Melissa Lopez, Ph.D., RDN, at the American Society of Hematology (ASH) annual meeting in Orlando. Lopez is a postdoctoral ...
A sound defense: Noisy pupae puff away potential predators
2025-12-07
Insect pupae hiss like snakes for defense. A Kobe University team now reveals the mechanisms, opening the door to further studies involving predator reactions to defensive sounds.
Just as you would shout or make noise to drive off a perceived threat, some insects have been known to produce defensive sounds. Some moths, for example, have been observed producing sounds to ward off predators at multiple developmental stages; pupal sound production has so far been attributed mainly to physical friction between body parts. “We became interested in this topic when ...
Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy
2025-12-07
(ORLANDO, Dec. 7, 2025) In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen of azacitidine and venetoclax compared with conventional induction chemotherapy. The azacitidine–venetoclax combination (known as aza-ven) is the standard of care for older adults who are not fit enough for intensive chemotherapy. The trial is the first to test the superiority of this regimen to intensive induction chemotherapy, the current standard for fit patients.
“Our study met ...
Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes
2025-12-07
(ORLANDO, Dec. 7, 2025) In a new trial, patients with follicular lymphoma had a significantly higher response to treatment and a nearly 80% reduction in the risk of death or disease progression if they received epcoritamab in addition to the standard second-line regimen versus the standard regimen alone. The study is the first reported randomized controlled trial to test a bispecific antibody combination in follicular lymphoma and suggests the combination could offer an effective alternative to chemotherapy that can be safely administered on an outpatient basis.
Based on the study results, the U.S. Food and Drug Administration (FDA) approved epcoritamab with ...
New findings support a chemo-free approach for treating Ph+ ALL
2025-12-07
(ORLANDO, Dec. 7, 2025) A chemotherapy-free combination treatment outperformed a combination of targeted therapy and chemotherapy among patients with Ph+ acute lymphoblastic leukemia (ALL) in a new study. The phase III trial, which included adult patients with no upper age limit, is the first formal comparison of the efficacy and safety of these two approaches in newly diagnosed patients with Ph+ ALL.
Researchers say the findings offer reassurance that chemotherapy can be omitted without detrimental effects and suggest that a chemo-free targeted agent and immunotherapy combination could become the new standard of care for this patient group.
“The chemo-free approach ...
Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL
2025-12-07
(ORLANDO, Dec. 7, 2025) Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib, a covalent BTK inhibitor. Based on the study results, researchers suggest pirtobrutinib shows promise as initial BTK inhibitor therapy, including in the frontline setting, for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).
Non-covalent BTK inhibitors were initially developed to overcome resistance to covalent ...
LAST 30 PRESS RELEASES:
Weaving secondary battery electrodes with fibers and tying them like ropes for both durability and performance
Using social media may impair children’s attention
Science briefing: An update on GLP-1 drugs for obesity
Lower doses of immunotherapy for skin cancer give better results
Why didn’t the senior citizen cross the road? Slower crossings may help people with reduced mobility
ASH 2025: Study suggests that a virtual program focusing on diet and exercise can help reduce side effects of lymphoma treatment
A sound defense: Noisy pupae puff away potential predators
Azacitidine–venetoclax combination outperforms standard care in acute myeloid leukemia patients eligible for intensive chemotherapy
Adding epcoritamab to standard second-line therapy improves follicular lymphoma outcomes
New findings support a chemo-free approach for treating Ph+ ALL
Non-covalent btki pirtobrutinib shows promise as frontline therapy for CLL/SLL
University of Cincinnati experts present research at annual hematology event
ASH 2025: Antibody therapy eradicates traces of multiple myeloma in preliminary trial
ASH 2025: AI uncovers how DNA architecture failures trigger blood cancer
ASH 2025: New study shows that patients can safely receive stem cell transplants from mismatched, unrelated donors
Protective regimen allows successful stem cell transplant even without close genetic match between donor and recipient
Continuous and fixed-duration treatments result in similar outcomes for CLL
Measurable residual disease shows strong potential as an early indicator of survival in patients with acute myeloid leukemia
Chemotherapy and radiation are comparable as pre-transplant conditioning for patients with b-acute lymphoblastic leukemia who have no measurable residual disease
Roughly one-third of families with children being treated for leukemia struggle to pay living expenses
Quality improvement project results in increased screening and treatment for iron deficiency in pregnancy
IV iron improves survival, increases hemoglobin in hospitalized patients with iron-deficiency anemia and an acute infection
Black patients with acute myeloid leukemia are younger at diagnosis and experience poorer survival outcomes than White patients
Emergency departments fall short on delivering timely treatment for sickle cell pain
Study shows no clear evidence of harm from hydroxyurea use during pregnancy
Long-term outlook is positive for most after hematopoietic cell transplant for sickle cell disease
Study offers real-world data on commercial implementation of gene therapies for sickle cell disease and beta thalassemia
Early results suggest exa-cel gene therapy works well in children
NTIDE: Disability employment holds steady after data hiatus
Social lives of viruses affect antiviral resistance
[Press-News.org] Weaving secondary battery electrodes with fibers and tying them like ropes for both durability and performanceKIER’s ‘Dual-Fiber’ dry electrode technology overcomes limits of conventional battery electrode manufacturing.